Pipeline

Robust Product Pipeline

Our rich pipeline of product candidates demonstrates our leadership in drug development for central nervous system (CNS) diseases, a therapeutic area where we have a proven track record of success. Backed by decades of experience, we are able to streamline clinical development time and substantially increase the probability of late-stage product success. The proof is in our substantial pipeline and its potential to have a unique and positive impact for patients.

Development Candidates

Preclinical Phase 1 Phase 2 Phase 3 FDA Submission
ALKS 5461
(Major Depressive Disorder)

Aripiprazole Lauroxil NanoCrystal® Dispersion
(Initiation product for ARISTADA®)

ALKS 3831
(Schizophrenia)

BIIB098 (formerly ALKS 8700)
(Multiple Sclerosis)

ALKS 4230
(Immuno-oncology)

Learn more about our portfolio of innovative products.